📊 IMCR Key Takeaways
Is IMCR a Good Investment? Thesis Analysis
Immunocore demonstrates strong revenue growth (+29% YoY) with significantly improving losses (-30.5% improvement), but persistent operating cash burn and negative profitability create execution risk. Adequate cash reserves ($467.7M) provide runway, yet achievement of near-term profitability is critical to justify leverage and operational model.
Why Buy IMCR? Key Strengths
- Strong revenue growth of 29% YoY demonstrates market traction and product demand
- Significant loss improvement of 30.5% YoY net income shows trajectory toward profitability
- Excellent liquidity with $467.7M cash and 4.04x current ratio provides 18+ month operational runway
IMCR Investment Risks to Consider
- Operational cash burn of -$10.7M and negative free cash flow of -$15.1M despite revenue growth signals operational inefficiency
- Inability to cover interest payments from operations (Interest Coverage -3.7x) with elevated debt position of $438.7M
- Sustained unprofitability with negative ROE (-9.3%) and ROA (-3.3%) raises questions about business unit economics
Key Metrics to Watch
- Path to operating cash flow positivity and near-term profitability timeline
- Gross margin realization if disclosed, as it indicates product-level unit economics
- Debt reduction progress and interest coverage trajectory
IMCR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.04x current ratio provides a solid financial cushion.
IMCR Profitability Ratios
IMCR vs Healthcare Sector
How Immunocore Holdings plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IMCR Overvalued or Undervalued?
Based on fundamental analysis, Immunocore Holdings plc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IMCR Balance Sheet & Liquidity
IMCR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Immunocore Holdings plc's revenue has grown significantly by 68% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.13 indicates the company is currently unprofitable.
IMCR Growth Metrics (YoY)
IMCR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $80.2M | -$177.0K | $0.00 |
| Q2 2025 | $75.4M | $5.0M | $-0.11 |
| Q1 2025 | $70.5M | $5.0M | $0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IMCR Capital Allocation
IMCR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Immunocore Holdings plc (CIK: 0001671927)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMCR
What is the AI rating for IMCR?
Immunocore Holdings plc (IMCR) has an AI rating of HOLD with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMCR's key strengths?
Claude: Strong revenue growth of 29% YoY demonstrates market traction and product demand. Significant loss improvement of 30.5% YoY net income shows trajectory toward profitability.
What are the risks of investing in IMCR?
Claude: Operational cash burn of -$10.7M and negative free cash flow of -$15.1M despite revenue growth signals operational inefficiency. Inability to cover interest payments from operations (Interest Coverage -3.7x) with elevated debt position of $438.7M.
What is IMCR's revenue and growth?
Immunocore Holdings plc reported revenue of $400.0M.
Does IMCR pay dividends?
Immunocore Holdings plc does not currently pay dividends.
Where can I find IMCR SEC filings?
Official SEC filings for Immunocore Holdings plc (CIK: 0001671927) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMCR's EPS?
Immunocore Holdings plc has a diluted EPS of $-0.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMCR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Immunocore Holdings plc has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMCR stock overvalued or undervalued?
Valuation metrics for IMCR: ROE of -9.3% (sector avg: 15%), net margin of -8.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMCR stock in 2026?
Our dual AI analysis gives Immunocore Holdings plc a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMCR's free cash flow?
Immunocore Holdings plc's operating cash flow is $-10.7M, with capital expenditures of $4.3M. FCF margin is -3.8%.
How does IMCR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.9% (avg: 12%), ROE -9.3% (avg: 15%), current ratio 4.04 (avg: 2).